EssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression

Dow Jones

Sep 26

By Kelly Cloonan

EssilorLuxottica has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children.

The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally.

The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said.

Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life.

Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

September 25, 2025 18:05 ET (22:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2570404249"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570404249\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570404249?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570404249","market":"fut","top_or_hot":-1,"title":"EssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ESLOF\">EssilorLuxottica</a> has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children. \n</p>\n<p>\n  The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally. \n</p>\n<p>\n  The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said. \n</p>\n<p>\n  Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life. \n</p>\n<p>\n  Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 25, 2025 18:05 ET (22:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-26 06:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ESLOF\">EssilorLuxottica</a> has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children. \n</p>\n<p>\n  The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally. \n</p>\n<p>\n  The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said. \n</p>\n<p>\n  Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life. \n</p>\n<p>\n  Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 25, 2025 18:05 ET (22:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESLOY","symbol_name":"EssilorLuxottica","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2570404249","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570404249","pubTimestamp":1758837900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"EssilorLuxottica has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children.The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally.The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said.Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESLOY":"EssilorLuxottica","BK4202":"服装、服饰与奢侈品","BK1170":"电子元件","06613":"蓝思科技","BK4198":"医疗保健用品"},"translate_title":"EssilorLuxottica获得FDA批准用于减缓近视进展的镜片","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESLOY":0.9,"06613":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\nEssilorLuxottica has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children. \n\n\n  The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally. \n\n\n  The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said. \n\n\n  Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life. \n\n\n  Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 25, 2025 18:05 ET (22:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}